These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Allotype-specific processing of the CD16a N45-glycan from primary human natural killer cells and monocytes. Patel KR; Roberts JT; Barb AW Glycobiology; 2020 Jul; 30(7):427-432. PubMed ID: 31967297 [TBL] [Abstract][Full Text] [Related]
5. Site-specific N-glycan Analysis of Antibody-binding Fc γ Receptors from Primary Human Monocytes. Roberts JT; Patel KR; Barb AW Mol Cell Proteomics; 2020 Feb; 19(2):362-374. PubMed ID: 31888963 [TBL] [Abstract][Full Text] [Related]
6. Inhibiting N-glycan processing increases the antibody binding affinity and effector function of human natural killer cells. Rodriguez Benavente MC; Hughes HB; Kremer PG; Subedi GP; Barb AW Immunology; 2023 Oct; 170(2):202-213. PubMed ID: 37218360 [TBL] [Abstract][Full Text] [Related]
7. Primary Human Natural Killer Cells Retain Proinflammatory IgG1 at the Cell Surface and Express CD16a Glycoforms with Donor-dependent Variability. Patel KR; Nott JD; Barb AW Mol Cell Proteomics; 2019 Nov; 18(11):2178-2190. PubMed ID: 31467031 [TBL] [Abstract][Full Text] [Related]
8. The weaker-binding Fc γ receptor IIIa F158 allotype retains sensitivity to N-glycan composition and exhibits a destabilized antibody-binding interface. Kremer PG; Barb AW J Biol Chem; 2022 Sep; 298(9):102329. PubMed ID: 35921896 [TBL] [Abstract][Full Text] [Related]
9. Distinct CD16a features on human NK cells observed by flow cytometry correlate with increased ADCC. Benavente MCR; Hakeem ZA; Davis AR; Murray NB; Azadi P; Mace EM; Barb AW Sci Rep; 2024 Apr; 14(1):7938. PubMed ID: 38575779 [TBL] [Abstract][Full Text] [Related]
10. Antibody Fucosylation Lowers the FcγRIIIa/CD16a Affinity by Limiting the Conformations Sampled by the N162-Glycan. Falconer DJ; Subedi GP; Marcella AM; Barb AW ACS Chem Biol; 2018 Aug; 13(8):2179-2189. PubMed ID: 30016589 [TBL] [Abstract][Full Text] [Related]
11. One N-glycan regulates natural killer cell antibody-dependent cell-mediated cytotoxicity and modulates Fc γ receptor IIIa / CD16a structure. Kremer PG; Lampros EA; Blocker AM; Barb AW bioRxiv; 2024 Aug; ():. PubMed ID: 38948809 [TBL] [Abstract][Full Text] [Related]
12. A single amino acid distorts the Fc γ receptor IIIb/CD16b structure upon binding immunoglobulin G1 and reduces affinity relative to CD16a. Roberts JT; Barb AW J Biol Chem; 2018 Dec; 293(51):19899-19908. PubMed ID: 30361439 [TBL] [Abstract][Full Text] [Related]
13. Anti-ADAM17 monoclonal antibody MEDI3622 increases IFNγ production by human NK cells in the presence of antibody-bound tumor cells. Mishra HK; Pore N; Michelotti EF; Walcheck B Cancer Immunol Immunother; 2018 Sep; 67(9):1407-1416. PubMed ID: 29978334 [TBL] [Abstract][Full Text] [Related]
14. ADAM17-mediated shedding of FcγRIIIA on human NK cells: identification of the cleavage site and relationship with activation. Lajoie L; Congy-Jolivet N; Bolzec A; Gouilleux-Gruart V; Sicard E; Sung HC; Peiretti F; Moreau T; Vié H; Clémenceau B; Thibault G J Immunol; 2014 Jan; 192(2):741-51. PubMed ID: 24337742 [TBL] [Abstract][Full Text] [Related]
15. The antibody-binding Fc gamma receptor IIIa / CD16a is N-glycosylated with high occupancy at all five sites. Lampros EA; Kremer PG; Aguilar Díaz de León JS; Roberts ET; Rodriguez Benavente MC; Amster IJ; Barb AW Curr Res Immunol; 2022; 3():128-135. PubMed ID: 35712026 [TBL] [Abstract][Full Text] [Related]
16. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells. Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B Front Immunol; 2018; 9():2873. PubMed ID: 30574146 [TBL] [Abstract][Full Text] [Related]
17. Identification of an ADAM17 cleavage region in human CD16 (FcγRIII) and the engineering of a non-cleavable version of the receptor in NK cells. Jing Y; Ni Z; Wu J; Higgins L; Markowski TW; Kaufman DS; Walcheck B PLoS One; 2015; 10(3):e0121788. PubMed ID: 25816339 [TBL] [Abstract][Full Text] [Related]
18. Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. Victor AR; Weigel C; Scoville SD; Chan WK; Chatman K; Nemer MM; Mao C; Young KA; Zhang J; Yu J; Freud AG; Oakes CC; Caligiuri MA J Immunol; 2018 Jan; 200(2):565-572. PubMed ID: 29229679 [TBL] [Abstract][Full Text] [Related]
19. Examination of IgG Fc Receptor CD16A and CD64 Expression by Canine Leukocytes and Their ADCC Activity in Engineered NK Cells. Hullsiek R; Li Y; Snyder KM; Wang S; Di D; Borgatti A; Lee C; Moore PF; Zhu C; Fattori C; Modiano JF; Wu J; Walcheck B Front Immunol; 2022; 13():841859. PubMed ID: 35281028 [TBL] [Abstract][Full Text] [Related]
20. The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc γ receptor. Subedi GP; Barb AW MAbs; 2016; 8(8):1512-1524. PubMed ID: 27492264 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]